DEF 14A: ImmuCell Corporation Announces Annual Meeting of Stockholders to be Held on June 13, 2024

ImmuCell Corporation will hold its Annual Meeting of Stockholders remotely on June 13, 2024, to elect directors, vote on executive compensation, and ratify the appointment of its independent accounting firm.

Summary

• ImmuCell Corporation will hold its Annual Meeting of Stockholders on June 13, 2024, at 9:30 AM ET.
• The meeting will be conducted remotely via a live audio webcast and telephone conference call.
• Stockholders of record as of April 15, 2024, are entitled to vote.
• The agenda includes the election of directors, an advisory vote on executive compensation, and the ratification of Wipfli LLP as the independent registered public accounting firm for the year ending December 31, 2024.
• The Board of Directors recommends voting for all director nominees, for the advisory vote on executive compensation, and for the ratification of the accounting firm appointment.
• As of April 15, 2024, there were 7,824,186 shares of common stock issued and outstanding, each entitled to one vote.

Sentiment

Score: 7

Explanation: The document is primarily factual and procedural, outlining the agenda and procedures for the annual meeting. The tone is professional and neutral, with a slight positive leaning due to the board's recommendations to vote for all proposals.

Positives

• The Board of Directors is actively engaged, with high attendance rates at board and committee meetings.
• The company has a Code of Business Conduct and Ethics in place to promote ethical behavior and compliance.
• The Audit Committee includes members who meet the heightened independence and expertise requirements.
• The Nominating Committee values diversity in board membership.
• Stockholders have the opportunity to communicate directly with management and directors.

Negatives

• The company reported a net loss of $5,775,000 in 2023.
• Executive compensation includes accrued and unused paid time off for the CEO, which is a liability on the balance sheet.
• A related party transaction exists with a company controlled by the Chair of the Board, involving product purchases.

Risks

• The development and manufacture of efficacious products with and without regulatory approval is subject to considerable risk.
• The Audit Committee takes the lead on oversight of credit, liquidity and operational risk.
• The company does not have a specific risk management department.

Future Outlook

The management of the Company does not know of any business not specifically referred to above as to which any action is expected to be taken at the meeting. However, if any business other than those items referred to above properly comes before the meeting, it is the intention of the persons named in the enclosed form of proxy to vote such proxy in accordance with their judgment on such matters.

Management Comments

• Mr. Michael F. Brigham has served as President and CEO since February 2000.
• Dr. David S. Tomsche has served as Chair of the Board of Directors since February 2013.
• Ms. Bobbi Jo Brockmann has served as Vice President of Sales and Marketing since February 2015.
• Ms. Elizabeth L. Williams has served as Vice President of Manufacturing Operations since April 2016.

Industry Context

ImmuCell operates in the animal health industry, which is characterized by companies developing and marketing products for livestock. The company's focus on preventative health solutions aligns with the broader industry trend towards improving animal welfare and productivity.

Comparison to Industry Standards

• Executive compensation practices, such as the use of stock options and bonuses, are common in the animal health industry.
• Peer companies like Zoetis and Elanco also utilize similar compensation structures to attract and retain talent.
• The company's approach to corporate governance, including the establishment of independent committees and a code of ethics, aligns with industry best practices.

Related Party Transactions

• David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc., a domestic distributor of our products (the First Defense product line and CMT).
• His affiliated company purchased $231,405 and $587,677 of products from us during the years ended December 2023 and 2022, respectively, all on terms consistent with those offered to other distributors of similar status.
• Our accounts receivable (subject to standard and customary payment terms) due from this affiliated company aggregated $42,507 and $46,426 as of December 31, 2023 and 2022, respectively.

Stakeholder Impact

• Shareholders are asked to vote on key proposals that affect the company's governance and executive compensation.
• Employees are indirectly affected by the executive compensation decisions.
• The selection of the independent accounting firm impacts the credibility of the company's financial reporting.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The Annual Meeting will be held on June 13, 2024.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Board of Directors, Executive Compensation, Director Election, Audit Committee, Wipfli LLP, Independent Registered Public Accounting Firm, Corporate Governance